The Discounted Cash Flow (DCF) valuation of Karyopharm Therapeutics Inc (KPTI) is (210.93) USD. With the latest stock price at 4.65 USD, the upside of Karyopharm Therapeutics Inc based on DCF is -4636.2%.
Based on the latest price of 4.65 USD and our DCF valuation, Karyopharm Therapeutics Inc (KPTI) is a sell. selling KPTI stocks now will result in a potential gain of 4636.2%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.5% - 7.7% | 6.1% |
| Long-term Growth Rate | 3.0% - 4.2% | 3.6% |
| Fair Price | (1,823.31) - (125.43) | (210.93) |
| Upside | -39310.9% - -2797.5% | -4636.2% |